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LEITERS TO THE EDITOR 
HETEROGENOUS DISTRIBUTION OF CIDMERISM PRODUCED BY RAT ORGAN AND 
BONE MARROW ALLOTRANSPLANTATION 
We recently described a striking association of organ 
allograft acceptance and the quantity and quality of immu-
nocytochemically detectable donor leukocyte chimerism 
caused by previous ("priming") transplants (1). In these ex-
periments, 1.0 mg/kg/day tacrolimus on days 0-13 and single 
supplemental doses on days 20 and 27 were given intramus-
cularly to Brown Norway (EN, RT1n) recipients of primary 
Lewis (LEW, RT1l) orthotopic livers, bone marrow infusions, 
abdominally placed heart allografts (the Ono-Lindsey model 
[2J) and other kinds of organs and leukocyte suspensions. On 
day 100. after a drug-free interval of 73 days, the liver, bone 
marrow, and heart recipients accepted "challenge" liver and 
cardiac allografts from LEW strain donors for another 100 
days. At day 200, significant histopathologic findings of 
chronic rejection in the challenge hearts were absent, mini· 
mal. and most obvious in the animals originally primed with 
the livers, bone marrow, and hearts, respectively (1). 
Although the results in this investigation correlated gen-
erally with the degree and kind of chimerism produced by the 
priming allograft. the substantial but incomplete tolerance at 
100 days produced in primary heart recipients in whom do-
nor leukocytes could no longer be found with immunocyto-
chemical techniques prompted the following experiments. 
Hearts. livers. or bone marrow cells from male LEW donors 
were transplanted to female BN reCIpients under the same 
conditions as reported previously, including the short course 
uf tacrolimus. At 100 days. the animals were killed and their 
!Issues WE're studied with polvmerase chain reaction (PCR) 
. 111d ~()uthern hvbrldizatlOn. using rat Y-chromosome (sex 
determining !legion Y [SRY))-specific primers (3). This proce-
dure allowed detection of small numbers of male cells (to 
1150,000 recipient cells, 0.002%) in female recipients. 
Donor DNA was found in the spleen, native heart, liver, or 
thymus of the three heterotopic heart recipients treated by 
the previous protocol (group 1, Table 1). Five of the 14 sam-
ples, but only one in five from the spleen and lymph nodes, 
were positive. In two of the three animals, donor DNA was 
present at more than one site. As reported before (1), no cells 
were detected with immunocytochemistry. 
Three additional heart recipients (group 2) also were ad-
ministered 180 J.Lg/kglday rmGM-CSF (n=2) or 250 J.Lg/kglday 
rhG·CSF (n= 1) for 14 days (day 0-13l. Four of six spleen or 
lymph node samples contained donor DNA (Table 1) and two 
of these (in a GM-CSF-treated animal) were positive with 
immunocytochemistry. Although not conclusive, the greater 
yield from the spleen and lymph nodes of the growth factor-
treated heart recipients was consistent with our speculation 
(1) that the better control of rejection in liver transplant 
recipients treated with G-CSF reported by Foster et a1. (4) 
was due to an augmentation of spontaneous chimerism. 
In rats submitted to liver replacement (group 3), three of 
six samples from the spleen or a lymph node tested positive 
for donor DNA (Table 1l. In animal 357, the donor DNA was 
found only in the bone marrow (footnote d in tablel. Donor 
bone marrow infusion (group 4) produced the most ubiqui· 
tous chimerism of any kind of allograft with or without 
!_,'Towth factor therapy: 13 of 15 samples wer.e positive I Ta-
ble 1) . 
1'.\1\1.,: 1. :-;('1ll14uanttlatJon of Y-chromu,;ome-detected chimen,;m III reCIpIent tissues IOU davs after LEW male to BN female heart. liver. 
'Ind bone marrow transpi<Jntatl0n 
1 ,rOll!) :\ o. ! Jroct'Ourp" "ple"n I.vmpn nodt'!"I \' ,ttlVt' ht',lrt l"I\"I'r 
:11 HTX l!l,OOO-IO.OOO '.;Th 11 I 0 ,llll()-;'iO. 000 
l~ HTX 1/:;0.000 
;;'i6 HTX 11:;0.000 
19 IITX ~(;~ICSF 11l0.UOO 1110.000 '.;T :\T 
:c{i fITX ~ (; ~lCS F 1110.000 '.;T '.;T 
:c:l HTX -GCSF lilO.OOO :\T '.;T 
;09 \lLTX 1 1 ,000- 10,000 '.;,\ 
)10 llLTX l!l,OOO-IO.OOO 111.000-10.000 1/S0.000 :\"A 
'\ - .... 1 
,;,); tlLTX '.;A 
16 Fl~ITX 1110.000 UO.UOO 11lO.00O 11:;0.000 
:cO 13~lTX • G~ICSF l,' 1.000-10.000 1/')0.000 
:c~ Bl\ITX - C;CSF 1.1 .000- J(). OUU lilO.OOO 11:;0.000 I/\O.UOO 
Procpdun's: !lTX. heart transplantatIOn: (lLTX. h,'l'[ 1 ransplantatwn: Bl\ITX. bUIll' marrow transplantatIOn. 
'.;T. not t,·,;ted. 
'\ :\. ntlt applicable. 
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The heterogenous distribution of donor DNA was reminis-
cent of that in our original clinical studies (5) in which 27 (of 
27) human organ recipients had microchimerism 10-22 
years after liver or kidney transplantation. However, the 
donor leukocytes were frequently found in only one or two of 
the three systematically sampled sites (blood, skin.. and 
lymph node), with similar irregular distribution in other 
tissues not routinely obtained (heart, intestine, and bone 
marrow). Studies in rats (1, 6) and mice (7) also have under-
scored the warning that the absence of chimerism cannot be 
inferred from negative test results in limited tissue and blood 
samples. The best evidence is that the long survival of an 
organ allograft under the conditions of clinical transplanta-
tion, and in analogous animal models, means that chimerism 
is present. Failure to demonstrate it implies an incomplete 
search. 
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HEPATITIS C VIRUS AND TRANSPLANTATION 
The recent study of the impact of hepatitis C infection on 
the outcome of renal transplantation by Pereira et al. (Trans-
plantation 1995: 60(8): 799) raises the contentious issue of 
whether patients who harbor the hepatitis C virus should 
undergo renal transplantation at all. Little mention, how-
ever. is made in this heterogenous group of 23 hepatitis 
C -positive recipients of the presence at the time of trans plan-
tation of active liver disease as indicated by liver biopsy or 
l'levated liver enzvmes. In a retrospective study from our own 
~mgje mstltutlOnal experience. where 38 renal allogratt re-
Cipients were hepatitis C pOSitive at the time of surgery, all 
patients had normal liver enzymes (Kazi et a!.. Dig Dis Sci 
1994: 39: 961l. In eight of these patients overt liver disease 
developed alter transplant. compared with 14 of the 214 
[jon-hepatitis C patients. In two of the eight patients who 
received transplants. histoloRlcal evidence of chronic active 
ill'patitis developed. but no recIpient has succumbed to pro-
.:.:ressive liver disease (100'"< follow-up I. Chronic active hepa-
titis developed in six of the 1"* non-hepatitis C patients, and 
two died of cirrhosis: 10 of these 14 patients were hepatitis B 
positivp. Uur data therefore suggested that hepatitis C-pos-
Itlve potpntlal renal allograft reCipients with normal liver 
enzymes at the time of transplantation were at low risk for ~ 
the development of chronic liver disease in the posttrans-
plant period. In light of these findings, perhaps Dr. Pereira 
and colleagues would be willing to reanalyze their data to 
look at the outcome of the subset of hepatitis C-positive 
patients whose hepatitis appears to be quiescent, i.e., with a 
normal liver biopsy or liver enzymes at the time of trans plan-
tation? If indeed these latter recipients are at low risk, then 
the proscription against renal transplantation suggested by 
Pereira's group might not be applicable to this subset of 
patients. 
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IN SCPPORT OF THE Fe'WINGS OF CHRISTOPHER F. BRYA.."I ET A1. 
We haH' read With Interest the article by Dr. Bryan and 
co-workers I I' regarding the detectIOn of HLA IgG class I 
,tlloantlbodles I aAb) using enzyme-linked Immunoassays 
, ErA) 12 I. We have similarly performed an evaluatIOn of the 
PRA-STAT EIA kit 1 manufactured by SangStat !l.ledical 
('orp. and marketed by ;";extran. an atfiliate of Baxter 
Healthcarel and compared it With the standard ~NIH" C-
dependent CytotOXICity (CDC) and antiglobulin (ARG) CDC 
PRA screenmg methods i.3l. We find that in our laboratories 
as well, this commercial ElA kit cannot reliably detect HLA 
class I aAb. 
In our study. 30 HLA-specitic class I aAb (3 IgM and 27 IgG 
aAb) of reagent typmg quality and 150 sera, including blind 
duplicates and dilutIOns obtained from renal transplant can-
